Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
Frontiers in Oncology · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective cohort of 44 lung cancer patients (21 young ≤45 years, 23 elderly ≥75 years) reports that younger patients exhibited longer overall survival and more favorable genomic and inflammatory profiles. The study lacks statistical power, prospective design, and external validation; findings are descriptive and hypothesis-generating rather than definitive.
Retrospective cohort study. Patients with pathologically confirmed primary lung cancer diagnosed in 2022; stratified into young (≤45 years) and elderly (≥75 years) groups.. Intervention: Age stratification (≤45 years versus ≥75 years); treatment modalities examined included immunotherapy, targeted therapy, and surgery.. Compared with: Young versus elderly age groups; no randomised control group.. n = 44. Not reported in the source text..
Elderly patients had higher smoking exposure and worse nutritional–inflammatory profiles including lower albumin and prognostic nutritional index values Younger patients showed significantly longer OS (p-value not reported); PFS numerically longer but not statistically significant In univariate analyses, histology type, gene mutation status, and treatment modality were associated with survival outcomes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Findings suggest age-related differences in lung cancer presentation and prognosis, with potential implications for tailoring assessment and treatment decisions. However, the small sample size and retrospective design preclude firm clinical recommendations; results should be treated as hypothesis-generating pending validation in larger prospective cohorts.
Retrospective cohort with small sample (n=44), no comparator arm, and surrogate endpoints; findings are descriptive of age-related differences but lack statistical power and prospective design to guide clinical practice.
As stated by the source record.
Quoted from the source exactly as published.
Findings suggest age-related differences in lung cancer presentation and prognosis, with potential implications for tailoring assessment and treatment decisions. However, the small sample size and retrospective design preclude firm clinical recommendations; results should be treated as hypothesis-generating pending validation in larger prospective cohorts.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Lung cancer predominantly affects older adults; however, an increasing number of cases are diagnosed in younger patients. Age-related differences in baseline characteristics, survival outcomes, and prognostic factors remain incompletely understood. This study aimed to compare clinical features, laboratory profiles, and survival outcomes between young and elderly patients with lung cancer and to identify prognostic factors associated with overall survival (OS) and progression-free survival (PFS). Methods This retrospective cohort study screened patients with pathologically confirmed primary lung cancer diagnosed in 2022. Patients aged ≤45 years were classified as the young group, and those aged ≥75 years as the elderly group. Baseline demographic characteristics, laboratory parameters, and nutritional–inflammatory indices were compared between groups. Survival outcomes were evaluated using Kaplan–Meier analyses and compared with the log-rank test. Univariate and multivariate Cox proportional-hazards regression analyses were performed to identify prognostic factors for OS and PFS. Results A total of 44 patients were included (21 young, 23 elderly). Elderly patients had higher smoking exposure and worse nutritional and inflammatory profiles, including lower albumin and prognostic nutritional index values. Younger patients showed significantly longer OS, while PFS was numerically longer but not statistically significant despite a tendency toward more advanced disease. In univariate analyses, histology type, gene mutation status, and treatment modality were associated with survival outcomes. In the simplified multivariable Cox models, immunotherapy was independently associated with improved OS, and targeted therapy, surgery, and immunotherapy were associated with better PFS. Conclusions Young and elderly patients with lung cancer exhibit distinct clinical, laboratory, and survival profiles. Younger patients demonstrated more favorable genomic profiles and survival outcomes. These findings highlight the importance of age-specific evaluation and suggest that treatment-related and host-related factors should be considered in prognostic assessment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.